Gastric cancer (GC) represents a major health problem, remaining the fifth most common type of cancer and the third leading cause of cancer-related death worldwide with only few targeted therapies ava
Nivolumab might provide overall survival benefits for patients with advanced gastric cancer in Japan, South Korea, and Taiwan. However, it is effective in only a limited number of patients. Glasgow pr
Gastric cancer is the third leading cause of cancer death worldwide. Traditional Chinese medicine (TCM) is increasingly extensively applied as a complementary therapy for gastric cancer (GC) in China,
